Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 3:5:1-2.
doi: 10.1016/j.lrr.2015.11.001. eCollection 2016.

An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis

Burak Uz  1 , Ilhan Dolasik  1
Affiliations

An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis

Burak Uz et al. Leuk Res Rep. .

Abstract

We, herein, describe a 52-year-old male whom developed rhabdomyolysis and acute renal failure likely related to dasatinib shortly after the administration of treatment. After withdrawal of dasatinib, the myalgia reduced, and his CK returned to normal levels within a week. On follow-up acute renal failure did resolve without requiring dialysis, but unfortunately the patient died of severe respiratory distress. We recommend that musculoskeletal symptoms should be monitorized during therapy with dasatinib, and CML patients with musculoskeletal symptoms should have CK levels checked in order to prevent this unexpected but devastating adverse event.

Keywords: Creatine kinase; Dasatinib; Rhabdomyolysis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1
Close monitorisation of creatine kinase (CK) levels of the patient during follow-up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kantarjian H.M., Shah N.P., Cortes J.E., Baccarani M., Agarwal M.B., Undurraga M.S., Wang J., Ipiña J.J., Kim D.W., Ogura M., Pavlovsky C., Junghanss C., Milone J.H., Nicolini F.E., Robak T., Van Droogenbroeck J., Vellenga E., Bradley-Garelik M.B., Zhu C., Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood. 2012;119:1123–1129. - PMC - PubMed
    1. O’Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., Cowan-Jacop S.W., Lee F.Y., Heinrich M.C., Deininger M.W., Druker B.J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505. - PubMed
    1. 〈http://packageinserts.bms.com/pi/pi_sprycel.pdf〉
    1. Penel N., Blay J.Y., Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N. Engl. J. Med. 2008;358:2746–2747. - PubMed
    1. Gordon J.K., Magid S.K., Maki R.G., Fleisher M., Berman E. Elevations of creatine kinase in patients treated with imatinib mesylate (GleevecTM) Leuk. Res. 2010;34:827–829. - PubMed

LinkOut - more resources